Cargando…

Marriage of black phosphorus and Cu(2+) as effective photothermal agents for PET-guided combination cancer therapy

The use of photothermal agents (PTAs) in cancer photothermal therapy (PTT) has shown promising results in clinical studies. The rapid degradation of PTAs may address safety concerns but usually limits the photothermal stability required for efficacious treatment. Conversely, PTAs with high photother...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Kuan, Xie, Lin, Zhang, Yiding, Hanyu, Masayuki, Yang, Zhimin, Nagatsu, Kotaro, Suzuki, Hisashi, Ouyang, Jiang, Ji, Xiaoyuan, Wei, Junjie, Xu, Hao, Farokhzad, Omid C., Liang, Steven H., Wang, Lu, Tao, Wei, Zhang, Ming-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280494/
https://www.ncbi.nlm.nih.gov/pubmed/32513979
http://dx.doi.org/10.1038/s41467-020-16513-0
Descripción
Sumario:The use of photothermal agents (PTAs) in cancer photothermal therapy (PTT) has shown promising results in clinical studies. The rapid degradation of PTAs may address safety concerns but usually limits the photothermal stability required for efficacious treatment. Conversely, PTAs with high photothermal stability usually degrade slowly. The solutions that address the balance between the high photothermal stability and rapid degradation of PTAs are rare. Here, we report that the inherent Cu(2+)-capturing ability of black phosphorus (BP) can accelerate the degradation of BP, while also enhancing photothermal stability. The incorporation of Cu(2+) into BP@Cu nanostructures further enables chemodynamic therapy (CDT)-enhanced PTT. Moreover, by employing (64)Cu(2+), positron emission tomography (PET) imaging can be achieved for in vivo real-time and quantitative tracking. Therefore, our study not only introduces an “ideal” PTA that bypasses the limitations of PTAs, but also provides the proof-of-concept application of BP-based materials in PET-guided, CDT-enhanced combination cancer therapy.